On this page
Tevimbra
tislelizumab-jsgr
351(a) Standalone BLA
Overview
Source: Purple BookProprietary name
Tevimbra
Proper name
tislelizumab-jsgr
Licence type
351(a)
BLA number
761232
Applicant
BeiGene USA, Inc.
Center
CDER
Presentations
1
First licensure
—
Presentations
Source: Purple Book| Strength | Dosage form | Route | Presentation | Status | Licensed |
|---|---|---|---|---|---|
| 100MG/10ML (10MG/ML) | Injection | Intravenous | Single-Dose Vial | Rx | March 13, 2024 |
Exclusivity
Source: Purple Book| Kind | Expires |
|---|---|
| Orphan exclusivity | March 3, 1932 |
Sources for this page
| Purple Book | FDA | Licence type, presentations, reference product, exclusivity |